Environmental Risk Factors, Protective Factors, and Biomarkers for Allergic Rhinitis: A Systematic Umbrella Review of the Evidence

Author:

Xu Xianpeng,Liu Xinghong,Li Jiongke,Deng Xinxing,Dai Tianrong,Ji Qingjie,Xiong Dajing,Xie Hui

Abstract

AbstractMany potential environmental risk factors, protective factors, and biomarkers of AR have been published, but so far, the strength and consistency of their evidence are unclear. We conducted a comprehensive review of environmental risk, protective factors, and biomarkers for AR to establish the evidence hierarchy. We systematically searched Embase, PubMed, Cochrane Library, and Web of Science electronic database from inception to December 31, 2022. We calculated summary effect estimate (odds ratio (OR), relative risk (RR), hazard ratio (HR), and standardized mean difference (SMD)), 95% confidence interval, random effects p value, I2 statistic, 95% prediction interval, small study effects, and excess significance biases, and stratification of the level of evidence. Methodological quality was assessed by AMSTAR 2 (A Measurement Tool to Assess Systematic Reviews 2). We retrieved 4478 articles, of which 43 met the inclusion criteria. The 43 eligible articles identified 31 potential environmental risk factors (10,806,206 total population, two study not reported), 11 potential environmental protective factors (823,883 total population), and 34 potential biomarkers (158,716 total population) for meta-analyses. The credibility of evidence was convincing (class I) for tic disorders (OR = 2.89, 95% CI 2.11–3.95); and highly suggestive (class II) for early-life antibiotic use (OR = 3.73, 95% CI 3.06–4.55), exposure to indoor dampness (OR = 1.49, 95% CI 1.27–1.75), acetaminophen exposure (OR = 1.54, 95% CI 1.41–1.69), childhood acid suppressant use (OR = 1.40, 95% CI 1.23–1.59), exposure to indoor mold (OR = 1.66, 95% CI 1.26–2.18), coronavirus disease 2019 (OR = 0.11, 95% CI 0.06–0.22), and prolonged breastfeeding (OR = 0.72, 95% CI 0.65–0.79). This study is registered in PROSPERO (CRD42022384320).

Funder

National famous Traditional Chinese Medicine Inheritance Studio construction project

Publisher

Springer Science and Business Media LLC

Subject

General Medicine,Immunology and Allergy

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3